A detailed history of Avoro Capital Advisors LLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Avoro Capital Advisors LLC holds 3,541,505 shares of KURA stock, worth $31.9 Million. This represents 1.04% of its overall portfolio holdings.

Number of Shares
3,541,505
Previous 3,541,505 -0.0%
Holding current value
$31.9 Million
Previous $72.9 Million 5.1%
% of portfolio
1.04%
Previous 1.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$17.53 - $22.98 $5.41 Million - $7.09 Million
-308,495 Reduced 8.01%
3,541,505 $72.9 Million
Q1 2024

May 15, 2024

BUY
$13.42 - $23.53 $11.7 Million - $20.5 Million
870,000 Added 29.19%
3,850,000 $82.1 Million
Q3 2023

Nov 14, 2023

SELL
$8.44 - $11.86 $1.06 Million - $1.48 Million
-125,000 Reduced 4.03%
2,980,000 $27.2 Million
Q4 2022

Feb 14, 2023

SELL
$11.23 - $16.9 $4.72 Million - $7.1 Million
-420,000 Reduced 11.91%
3,105,000 $38.5 Million
Q3 2022

Nov 14, 2022

SELL
$12.01 - $19.45 $15.3 Million - $24.8 Million
-1,275,000 Reduced 26.56%
3,525,000 $48.2 Million
Q1 2022

May 16, 2022

BUY
$11.78 - $16.98 $9.42 Million - $13.6 Million
800,000 Added 20.0%
4,800,000 $77.2 Million
Q3 2021

Nov 15, 2021

SELL
$15.42 - $21.72 $2.16 Million - $3.04 Million
-140,000 Reduced 3.38%
4,000,000 $74.9 Million
Q2 2021

Aug 16, 2021

BUY
$20.85 - $29.88 $2.92 Million - $4.18 Million
140,000 Added 3.5%
4,140,000 $86.3 Million
Q4 2020

Feb 16, 2021

BUY
$29.0 - $41.62 $45.4 Million - $65.1 Million
1,565,000 Added 64.27%
4,000,000 $131 Million
Q3 2020

Nov 16, 2020

BUY
$16.3 - $30.64 $22.6 Million - $42.4 Million
1,385,000 Added 131.9%
2,435,000 $74.6 Million
Q2 2020

Aug 14, 2020

BUY
$7.95 - $18.81 $8.35 Million - $19.8 Million
1,050,000 New
1,050,000 $17.1 Million

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $603M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Avoro Capital Advisors LLC Portfolio

Follow Avoro Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avoro Capital Advisors LLC with notifications on news.